Technical Analysis for DMAC - DiaMedica Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Flat | Flat |
| Historical DMAC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 2.95% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 2.95% | |
| Lower Bollinger Band Touch | Weakness | 2.95% | |
| 20 DMA Resistance | Bearish | 3.97% | |
| 50 DMA Resistance | Bearish | 3.97% | |
| MACD Bearish Centerline Cross | Bearish | 3.97% | |
| Bollinger Band Squeeze | Range Contraction | 3.97% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 50 DMA Resistance | about 5 hours ago |
| 20 DMA Resistance | about 6 hours ago |
| Up 5% | about 6 hours ago |
| Rose Above 20 DMA | about 7 hours ago |
| Rose Above 50 DMA | about 7 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/04/2020
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Injury Kidney Disease Stroke Dementia Kidney Diseases Ischemia Kallikrein Ischemic Stroke Pancreatitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Injury Kidney Disease Stroke Dementia Kidney Diseases Ischemia Kallikrein Ischemic Stroke Pancreatitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.88 |
| 52 Week Low | 3.243 |
| Average Volume | 121,505 |
| 200-Day Moving Average | 6.86 |
| 50-Day Moving Average | 9.44 |
| 20-Day Moving Average | 9.46 |
| 10-Day Moving Average | 9.44 |
| Average True Range | 0.55 |
| ADX | 7.69 |
| +DI | 22.76 |
| -DI | 22.71 |
| Chandelier Exit (Long, 3 ATRs ) | 8.67 |
| Chandelier Exit (Short, 3 ATRs ) | 10.54 |
| Upper Bollinger Band | 9.98 |
| Lower Bollinger Band | 8.93 |
| Percent B (%b) | 0.47 |
| BandWidth | 11.09 |
| MACD Line | -0.04 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.0416 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.33 | ||||
| Resistance 3 (R3) | 10.30 | 9.96 | 10.18 | ||
| Resistance 2 (R2) | 9.96 | 9.73 | 9.98 | 10.13 | |
| Resistance 1 (R1) | 9.69 | 9.59 | 9.83 | 9.72 | 10.08 |
| Pivot Point | 9.36 | 9.36 | 9.43 | 9.37 | 9.36 |
| Support 1 (S1) | 9.09 | 9.13 | 9.22 | 9.12 | 8.76 |
| Support 2 (S2) | 8.75 | 8.98 | 8.77 | 8.71 | |
| Support 3 (S3) | 8.48 | 8.75 | 8.66 | ||
| Support 4 (S4) | 8.51 |
